Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person C5 binds C5 inhibitors

Class:IdReaction:9691621
_displayNameC5 binds C5 inhibitors
_doReleaseTRUE
_timestamp2025-08-18 14:16:59
authored[InstanceEdit:9724665] Jassal, Bijay, 2021-03-25
compartment[Compartment:984] extracellular region
created[InstanceEdit:9691596] Jassal, Bijay, 2020-06-18
edited[InstanceEdit:9757169] Jassal, Bijay, 2021-10-27
[InstanceEdit:9773839] Matthews, Lisa, 2022-05-10
[InstanceEdit:9963520] Shamovsky, Veronica, 2025-08-14
input[Complex:173676] C5 [extracellular region] [Homo sapiens]
[CandidateSet:9691614] C5 inhibitors [extracellular region]
isChimericFALSE
literatureReference[LiteratureReference:9691624] Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv
[LiteratureReference:9691608] Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
[LiteratureReference:9691593] Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action
[LiteratureReference:9691687] Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial
[LiteratureReference:9956954] C5 inhibitor avacincaptad pegol treatment for geographic atrophy: A comprehensive review
[LiteratureReference:9956959] Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape
[LiteratureReference:9956956] Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5
modified[InstanceEdit:9691647] Jassal, Bijay, 2020-06-18
[InstanceEdit:9691686] Jassal, Bijay, 2020-06-18
[InstanceEdit:9773229] Matthews, Lisa, 2022-05-03
[InstanceEdit:9773839] Matthews, Lisa, 2022-05-10
[InstanceEdit:9773858] Matthews, Lisa, 2022-05-10
[InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
[InstanceEdit:9956951] Shamovsky, Veronica, 2025-06-17
[InstanceEdit:9961906] Shamovsky, Veronica, 2025-07-28
[InstanceEdit:9963970] Shamovsky, Veronica, 2025-08-18
nameC5 binds C5 inhibitors
output[Complex:9691604] C5:C5 inhibitors [extracellular region] [Homo sapiens]
releaseDate2022-06-09
reviewed[InstanceEdit:9767610] Huddart, Rachel, 2022-03-01
[InstanceEdit:9961904] Duan, Huiquan, 2025-07-28
reviewStatus[ReviewStatus:9821382] five stars
species[Species:48887] Homo sapiens
stableIdentifier[StableIdentifier:9691629] R-HSA-9691621.3
summation[Summation:9691612] Activation of the complement system significantly contribute...
(hasEvent)[Pathway:174577] Activation of C3 and C5 [Homo sapiens]
(updatedInstance)[_UpdateTracker:9964641] Update Tracker - [Reaction:9691621] C5 binds C5 inhibitors - v94:[modifyText, removeLiteratureReference]
[Change default viewing format]
No pathways have been reviewed or authored by C5 binds C5 inhibitors (9691621)
Follow Reactome